MARKET

FENC

FENC

Fennec Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.07
+0.09
+1.51%
Closed 16:00 05/11 EDT
OPEN
5.84
PREV CLOSE
5.98
HIGH
6.21
LOW
5.80
VOLUME
54.87K
TURNOVER
--
52 WEEK HIGH
10.67
52 WEEK LOW
4.800
MARKET CAP
157.84M
P/E (TTM)
-7.9181
1D
5D
1M
3M
1Y
5Y
DJ Fennec Pharmaceuticals Initiated at Buy by Craig-Hallum
Dow Jones · 04/21 13:35
DJ Fennec Pharmaceuticals Price Target Announced at $17.00/Share by Craig-Hallum
Dow Jones · 04/21 13:35
DJ Fennec Pharmaceuticals Initiated at Buy by Maxim Group
Dow Jones · 04/19 14:15
DJ Fennec Pharmaceuticals Price Target Announced at $12.00/Share by Maxim Group
Dow Jones · 04/19 14:15
--Maxim Starts Fennec Pharmaceuticals at Buy with $12 Price Target
MT Newswires · 04/19 12:53
Analysts Are Optimistic We'll See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
We feel now is a pretty good time to analyse Fennec Pharmaceuticals Inc.'s ( NASDAQ:FENC ) business as it appears the...
Simply Wall St. · 04/04 10:54
BRIEF-Fennec Announces Fiscal Year 2020 Financial Results And Provides Business Update
reuters.com · 03/30 11:13
Fennec Pharmaceuticals EPS beats by $0.08
Fennec Pharmaceuticals (FENC): Q4 GAAP EPS of -$0.13 beats by $0.08.Revenue of $0.2MCash and cash equivalents of $30.3M as of December 31, 2020.Press Release
Seekingalpha · 03/30 10:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FENC. Analyze the recent business situations of Fennec Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FENC stock price target is 13.60 with a high estimate of 17.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 78
Institutional Holdings: 16.95M
% Owned: 65.18%
Shares Outstanding: 26.00M
TypeInstitutionsShares
Increased
20
917.71K
New
8
56.45K
Decreased
12
97.48K
Sold Out
8
191.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Khalid Islam
Chief Executive Officer/Director
Rostislav Raykov
Chief Financial Officer
Robert Andrade
Other
Shubh Goel
Independent Director
Marco Brughera
Independent Director
Jodi Cook
Independent Director
Adrian Haigh
Independent Director
Chris Rallis
No Data
About FENC
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Webull offers kinds of Fennec Pharmaceuticals Inc stock information, including NASDAQ:FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.